Adverse events690

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 690

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anaemia	Blood and lymphatic system disorders	DLT Period (Part A): CAEL-101 500 mg/m^2	0	4
other	Anaemia	Blood and lymphatic system disorders	DLT Period (Part A): CAEL-101 750 mg/m^2	0	3
other	Anaemia	Blood and lymphatic system disorders	DLT Period (Part A): CAEL-101 1000 mg/m^2	2	6
other	Anaemia	Blood and lymphatic system disorders	Overall (Part A): DLT + Continued Treatment Period: CAEL-101 Combined With SoC CyBorD	7	13	11
other	Anaemia	Blood and lymphatic system disorders	Continued Treatment Period (Part B): CAEL-101 Combined With SoC CyBorD and Daratumumab	4	12	7
other	Thrombocytopenia	Blood and lymphatic system disorders	DLT Period (Part A): CAEL-101 500 mg/m^2	0	4
other	Thrombocytopenia	Blood and lymphatic system disorders	DLT Period (Part A): CAEL-101 750 mg/m^2	0	3
other	Thrombocytopenia	Blood and lymphatic system disorders	DLT Period (Part A): CAEL-101 1000 mg/m^2	0	6
other	Thrombocytopenia	Blood and lymphatic system disorders	Overall (Part A): DLT + Continued Treatment Period: CAEL-101 Combined With SoC CyBorD	0	13	0
other	Thrombocytopenia	Blood and lymphatic system disorders	Continued Treatment Period (Part B): CAEL-101 Combined With SoC CyBorD and Daratumumab	2	12	2
other	Atrial Fibrillation	Cardiac disorders	DLT Period (Part A): CAEL-101 500 mg/m^2	0	4
other	Atrial Fibrillation	Cardiac disorders	DLT Period (Part A): CAEL-101 750 mg/m^2	0	3
other	Atrial Fibrillation	Cardiac disorders	DLT Period (Part A): CAEL-101 1000 mg/m^2	0	6
other	Atrial Fibrillation	Cardiac disorders	Overall (Part A): DLT + Continued Treatment Period: CAEL-101 Combined With SoC CyBorD	1	13	2
other	Atrial Fibrillation	Cardiac disorders	Continued Treatment Period (Part B): CAEL-101 Combined With SoC CyBorD and Daratumumab	1	12	1
other	Palpitations	Cardiac disorders	DLT Period (Part A): CAEL-101 500 mg/m^2	0	4
other	Palpitations	Cardiac disorders	DLT Period (Part A): CAEL-101 750 mg/m^2	0	3
other	Palpitations	Cardiac disorders	DLT Period (Part A): CAEL-101 1000 mg/m^2	0	6
other	Palpitations	Cardiac disorders	Overall (Part A): DLT + Continued Treatment Period: CAEL-101 Combined With SoC CyBorD	1	13	1
other	Palpitations	Cardiac disorders	Continued Treatment Period (Part B): CAEL-101 Combined With SoC CyBorD and Daratumumab	1	12	1

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04304144/events

API reference For AI assistants

Adverse events690

Sources 3

Read this list from software.